Kim Kyu Shik, Jeong Tae Yoong, Moon Hong Sang
Department of Urology, Myongji Hospital, Hanyang University College of Medicine, Goyang.
Department of Urology, Hanyang University Hospital, Hanyang University College of Medicine, Seoul, Korea.
Medicine (Baltimore). 2020 Jun 5;99(23):e20546. doi: 10.1097/MD.0000000000020546.
Erectile dysfunction (ED) and depression are closely related. We sought to determine ED and depression were improved by tadalafil, a phosphodiesterase type 5 (PDE5) inhibitor, at 5 mg daily, in this case-control study.Participants were men aged 20 to 65 years with ED for >3 months, International Index of Erectile Function-5 (IIEF) score <21 points, and Zung Self-Rating Depression Scale (SDS) survey result >50 points who were willing to participate.On first visit (V1) and after 1 (V2) and 2 months (V3), clinical features were examined using IIEF-5 for diagnosing and evaluating ED, SDS for evaluating depression, and International Prostate Symptom Score and Quality of Life (IPSS/QoL) survey for examining lower urinary tract symptoms (LUTS). Tadalafil 5 mg was administered daily for 2 months.A total of 60 participants were an average age of 58.68 ± 6.71 years. Patient overall average IIEF was 8.76 ± 5.98, showing mild ED symptoms, and total average IPSS 13.74 ± 7.55 showed moderate LUTS. Average overall SDS index was 58.93 ± 9.21, indicating moderate-to-severe findings. Average change in IIEF among all patients revealed significant improvement from V1 to V2 (-2.69 ± 1.22, P = .03) and V1 to V3 (-4.38 ± 1.20, P < 0.01). IPSS also significantly improved from V1 to V3 (3.48 ± 1.37, P = .01), as did SDS index (V1, V2: 4.69 ± 1.89, P = 0.02), (V1, V3: 5.43 ± 1.89, P < .01). Patients with severe IIEF scores (group 1, n = 27) experienced significantly greater improvement in IIEF from V1 to V2 and V1 and V3, compared to those with mild-to-moderate IIEF scores. Both groups improved in SDS index from V1 to V2 and V1 to V3, with the greatest improvement between V1 and V3 for group 1 and V1 and V2 for group 2.Daily tadalafil 5 mg could be helpful for ED patients with depressive symptoms and improved LUTS and quality of life.
勃起功能障碍（ED）与抑郁症密切相关。在这项病例对照研究中，我们试图确定每日服用5毫克磷酸二酯酶5型（PDE5）抑制剂他达拉非是否能改善ED和抑郁症。
研究对象为年龄在20至65岁之间、患有ED超过3个月、国际勃起功能指数-5（IIEF-5）评分低于21分且zung自评抑郁量表（SDS）调查结果高于50分且愿意参与的男性。
在首次就诊（V1）以及1个月（V2）和2个月（V3）后，使用IIEF-5来诊断和评估ED，SDS来评估抑郁，国际前列腺症状评分和生活质量（IPSS/QoL）调查来检查下尿路症状（LUTS）。每天服用5毫克他达拉非，持续2个月。
共有60名参与者，平均年龄为58.68±6.71岁。患者的总体平均IIEF为8.76±5.98，显示有轻度ED症状，总体平均IPSS为13.74±7.55，显示有中度LUTS。总体平均SDS指数为58.93±9.21，表明为中度至重度结果。所有患者IIEF的平均变化显示从V1到V2（-2.69±1.22，P = 0.03）和从V1到V3（-4.38±1.20，P < 0.01）有显著改善。IPSS从V1到V3也有显著改善（3.48±1.37，P = 0.01），SDS指数也是如此（V1，V2：4.69±1.89，P = 0.02），（V1，V3：5.43±1.89，P < 0.01）。与轻度至中度IIEF评分的患者相比，IIEF评分严重的患者（第1组，n = 27）从V1到V2以及从V1到V3的IIEF改善更为显著。两组从V1到V2以及从V1到V3的SDS指数均有所改善，第1组在V1和V3之间改善最大，第2组在V1和V2之间改善最大。
每日服用5毫克他达拉非可能有助于改善有抑郁症状的ED患者的LUTS和生活质量。
